The UNION team and advisors account for more than 20 drug approvals generating annual revenues in excess of 5 B USD.


Dr. Rasmus Toft-Kehler, Chief Executive Officer

Rasmus Toft-Kehler is the co-founder and board member of multiple biotech companies in the fields of microbiome research, immunology, and antibiotic resistance. Prior to entering biotech, Rasmus worked in leading investment banks and in management consulting, and as a board member of a family-owned enterprise that was sold in 2005.

Rasmus is the inventor of 5+ patents and has published research in leading entrepreneurship and scientific journals such as Journal of Business Venturing and Nature Reviews Microbiology.

Rasmus holds a Ph.D. in entrepreneurship from Copenhagen Business School with research stays at New York University and University of Cambridge as well as Harvard Business School.

In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.


Dr. Morten Sommer, Chief Scientific Officer

Morten Sommer is the co-founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research.

Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ Ph.Ds and Post-Doctorial researchers working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents, patent applications and author of scientific papers in journals such as Science, Cell and Nature and was named Top 10 under 40 on Genetic Engineering and Biotechnology News list of Biopharma Research and Business executives.

Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.


Dr. Philippe Prokocimer, Chief Medical Officer

Dr. Philippe Prokocimer, M.D. is the Chief Medical Officer of UNION. Dr. Prokocimer was CMO of Trius Therapeutics from July 2007 until its acquisition by Cubist in 2014. At Cubist, Dr. Prokocimer became Senior Vice President of Clinical Development until the acquisition by Merck in January 2015. At Merck, he became the Head of Merck’s San Diego site.

Philippe has been developing drugs for 30 years and has been involved with successful approval of 6 New Drug Applications including 5 antibiotics: Doripenem (Doribax®), Quinupristin/dalfopristin (Synercid®), Sparfloxacin (Zagam®), Clarithromycin (Biaxin®) and Tedizolid Phosphate (Sivextros®).

Philippe received an M.D. degree from the School of Medicine in Paris, France and a Post-Doctoral Research Fellowship from Stanford University.


Morten Boesen, Chief Financial Officer

Since 2011 he has worked with EQT, the largest private equity fund in the Nordics, first as an investment manager and subsequently as an executive director in EQT-owned retail company Flying Tiger Copenhagen, where he held responsibility for strategy, business development as well as global commercial and supply chain operations. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank and in the finance department of Novozymes, the world leader in industrial biotech.

Morten holds a M.Sc. in Finance and Accounting from Copenhagen Business School, including studies at New York University’s Stern School of Business and Tsinghua University’s School of Economics and Management.


Dr. Umar Hayat, VP of CMC and Supply Chain

Umar Hayat, PhD. has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa (acquired by Galenica for 1.5B US$), Anacor (acquired by Pfizer for 5.2B US$) and Transcept Pharmaceuticals (merged with Paratek). He played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis.

Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.


Dr. Lutz Wevelsiep, VP of Regulatory Affairs

Dr. Lutz Wevelsiep, Ph.D. is the Vice President of Regulatory Affairs at UNION and has more than 25 years’ experience in international Regulatory Affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. He has prepared and managed various health authority interactions with FDA, EMA and EU national agencies.

Lutz has spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®).

Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.


Mads Jellingsø, VP of Commercialization

Mads Jellingsø has broad Market Access experience from Novo Nordisk A/S where he was part of building new functions for Real World Evidence generation and for Innovative Contracting. In these teams Mads was driving Novo Nordisk’s global efforts to initiate partnerships with payers and providers around evidence generation and developing new financial and outcomes-based approaches to secure access for products in hemophilia, diabetes and obesity. Prior to specializing in Market Access, Mads has worked with off-shoring and legal affairs in Novo Nordisk and also has experience from management consulting (McKinsey & Company) and banking (Nordea Markets).

Mads holds a M.Sc. in Economics from University of Copenhagen.


Dr. Jan Trofast, VP of Patent Strategy

Jan Trofast is the co-inventor of Symbicort (annual sales >4 Billion USD) and the strategist behind a highly successful patent portfolio of 25+ patents protecting Symbicort and related products.

Jan Trofast has more than 30 years of experience from AstraZeneca including a number of years with evaluation of internal and external projects. In addition to his substantial achievements within drug development Jan is an accomplished author of a significant scientific literature including several publications related to Jacob Berzelius. For his contributions he has been rewarded the Berzelius medal in gold by the Royal Swedish Academy of Sciences in 2001 and the Swedish Medicinal Chemistry Award by the Swedish Pharmaceutical Society in 2010.

Jan Trofast obtained a Ph.D. in Organic Chemistry in 1978.



Learn more